re: bta unchanged in us overnight Share price has gone from 60...

re: bta unchanged in us overnight Share price has gone from 60 cents to $1.40 odd, since news first broke of the German order and stockpiling. That is an increase of market cap of A$170 million, including the SPP. $30 million cash from the SPP, so in nett terms, an increase in the value of the company of only $140 million. (How much more is Lani and likely court case-nothing it would seem, according to the market)

GSK and Biota share profits from Relenza sales. Biota get their percentage of sales as royalty for nil effort on their part. GSK have to make the product,(its expensive to make) distribute and pay BTA royalties, etc. So since Germany, if Relenza is only worth an extra $140, go figure, probably about $1.4 million to GSK. Thats $1.4 MILLION, GSK is a $200 BILLION company.

If aussie investors are correct with their value of Biota, then GSK senior management need to look at their time management, as do brokerage houses around the world and comments attributed to positive GSK price movement because of anti-viral sales (Relelnza).

The extra $140 million (since day 1, so to speak),means Biota has to receive royalties from sales of an extra 8 million doses per year (calculated at a PE oF 8 -includes their big tax losses) but NOT including additional value of LANI or the court case.